BioStem Technologies, Inc.

BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options

BioStem Technologies' Chair and CEO Jason Matuszewski and COO Andrew Van Vurst each exercised options for 250,000 shares at $2.00 per share, paying approximately $1 million in aggregate cash to the company. Both executives framed the exercises as a vote of confidence, with the capital earmarked to support sales coverage, hospital formulary expansion, and inventory for new accounts. Option exercises by insiders inject cash into the company but also add 500,000 shares of dilution; the modest size caps the market significance of the event.

•24d ago

BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio

BioStem Technologies announced the USPTO issued one new patent and three notices of allowance, with Mexico's IMPI issuing one additional notice of allowance, across its placental and umbilical cord tissue technologies. The patents cover sterile human placental allografts for wounds and diabetic foot ulcers, micronized umbilical cord compositions for wound healing, and umbilical cord extracts for joint cushioning and inflammation treatment. The company's IP portfolio now includes more than 100 patents and applications worldwide, supporting its wound care, surgical and joint allograft products.

•1mo ago

BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier

BioStem Technologies' VENDAJE and VENDAJE AC placental-derived tissue allografts are now available for order under the company's existing contracts with Vizient and Premier, effective immediately — the first GPO contract coverage for either product. Vizient is the largest GPO in the United States by affiliated staffed beds, serving more than 5,000 hospitals, and Premier is the second largest, serving more than 4,000, according to figures published by the organizations. The listings let clinicians in Vizient and Premier member hospitals order the BioRetain-process wound care products through existing contracting channels, removing a prior access barrier as BioStem pushes to reach health systems and providers at scale.

•1mo ago

BioStem Technologies Reports Second Quarter 2026 Financial Results

BioStem reported Q2 revenue of $7.9 million, representing 29% sequential growth from the first quarter, driven by sales of Neox and Clarix products, while maintaining a gross margin of 61%. The company raised its full-year 2026 revenue guidance to a range of $26 million to $29 million and completed an uplisting to the Nasdaq Capital Market on August 7, 2026. GAAP net loss for the quarter was ($9.0) million, or ($0.52) per share, and cash and cash equivalents decreased to $7.0 million as the company closed a $2.5 million private placement and resolved $5.3 million in debt.

•2mo ago

BioStem Technologies Publicly Files Form 10 Registration Statement with the Securities and Exchange Commission

BioStem Technologies filed a Form 10 registration statement with the SEC to register its common stock under the Securities Exchange Act of 1934, reaffirming its plan to uplist to the Nasdaq Stock Market. CEO Jason Matuszewski noted that the filing reflects a commitment to operating as an SEC reporting company and is expected to enhance credibility, access to capital, and liquidity. The company’s common stock will continue to trade on the OTC market under the ticker symbol BSEM until the registration statement is declared effective and the uplisting is completed.

•3mo ago

BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies

BioStem Technologies secured four U.S. design patents covering its fenestrated human placental allograft technologies, specifically protecting designs aimed at improving fluid management and conformability in wound care. The issuance expands the company's intellectual property portfolio, which now includes more than 100 patents and patent applications worldwide. Management emphasized that strengthening the IP foundation supports the long-term growth strategy for its regenerative medicine solutions.

•3mo ago

BioStem Technologies Announces Notice of Allowance for Four U.S. Design Patent Applications Covering Fenestrated Human Placental Allografts and One European Patent

BioStem Technologies announced that the USPTO issued Notices of Allowance for four U.S. design patents covering its fenestrated human placental allograft technologies. The European Patent Office also granted a new patent for sterile human placental allografts and proprietary manufacturing methods that preserve growth factors. These additions bring the company’s total global patent portfolio to more than 70, reinforcing its intellectual property moat in the regenerative medicine space.

•5mo ago

BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer

BioStem Technologies appointed Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026, to strengthen governance as the company targets a Nasdaq uplisting. Ms. Gorrell brings extensive experience from Holy Cross Health and AdvancedMD, focusing on health law, regulatory compliance, and operational excellence. This hire is intended to support the company's next phase of growth and ensure its legal and compliance frameworks evolve with the business.

•6mo ago